1. Home
  2. GLUE vs ALLT Comparison

GLUE vs ALLT Comparison

Compare GLUE & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • ALLT
  • Stock Information
  • Founded
  • GLUE 2019
  • ALLT 1996
  • Country
  • GLUE United States
  • ALLT Israel
  • Employees
  • GLUE N/A
  • ALLT N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • ALLT Telecommunications Equipment
  • Sector
  • GLUE Health Care
  • ALLT Telecommunications
  • Exchange
  • GLUE Nasdaq
  • ALLT Nasdaq
  • Market Cap
  • GLUE 351.2M
  • ALLT 342.5M
  • IPO Year
  • GLUE 2021
  • ALLT 2006
  • Fundamental
  • Price
  • GLUE $4.80
  • ALLT $7.86
  • Analyst Decision
  • GLUE Buy
  • ALLT Buy
  • Analyst Count
  • GLUE 2
  • ALLT 1
  • Target Price
  • GLUE $13.50
  • ALLT N/A
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • ALLT 535.2K
  • Earning Date
  • GLUE 08-07-2025
  • ALLT 08-14-2025
  • Dividend Yield
  • GLUE N/A
  • ALLT N/A
  • EPS Growth
  • GLUE N/A
  • ALLT N/A
  • EPS
  • GLUE 0.29
  • ALLT N/A
  • Revenue
  • GLUE $177,986,000.00
  • ALLT $95,342,000.00
  • Revenue This Year
  • GLUE $83.76
  • ALLT $10.64
  • Revenue Next Year
  • GLUE N/A
  • ALLT $15.76
  • P/E Ratio
  • GLUE $16.32
  • ALLT N/A
  • Revenue Growth
  • GLUE 2990.57
  • ALLT 4.74
  • 52 Week Low
  • GLUE $3.50
  • ALLT $2.75
  • 52 Week High
  • GLUE $12.40
  • ALLT $10.77
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • ALLT 51.18
  • Support Level
  • GLUE $4.54
  • ALLT $7.71
  • Resistance Level
  • GLUE $4.93
  • ALLT $8.10
  • Average True Range (ATR)
  • GLUE 0.21
  • ALLT 0.44
  • MACD
  • GLUE 0.06
  • ALLT 0.09
  • Stochastic Oscillator
  • GLUE 81.43
  • ALLT 59.12

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

Share on Social Networks: